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Abstract
Background: Ensuring that all cancer patients have access to the appropriate treatment within an appropriate time
is a strategic priority in many countries. There is in particular a need to describe and analyse cancer care trajectories
and to produce waiting time indicators. We developed an algorithm for extracting temporally represented care
trajectories from coded information collected routinely by the general cancer Registry in Poitou-Charentes region,
France. The present work aimed to assess the performance of this algorithm on real-life patient data in the setting
of non-metastatic breast cancer, using measures of similarity.
Methods: Care trajectories were modeled as ordered dated events aggregated into states, the granularity of which
was defined from standard care guidelines. The algorithm generates each state from the aggregation over a period
of tracer events characterised on the basis of diagnoses and medical procedures. The sequences are presented in
simple form showing presence and order of the states, and in an extended form that integrates the duration of the
states. The similarity of the sequences, which are represented in the form of chains of characters, was calculated
using a generalised Levenshtein distance.
Results: The evaluation was performed on a sample of 159 female patients whose itineraries were also calculated
manually from medical records using the same aggregation rules and dating system as the algorithm. Ninety-eight
per cent of the trajectories were correctly reconstructed with respect to the ordering of states. When the duration
of states was taken into account, 94% of the trajectories matched reality within three days. Dissimilarities between
sequences were mainly due to the absence of certain pathology reports and to coding anomalies in hospitalisation
data.
Conclusions: These results show the ability of an integrated regional information system to formalise care
trajectories and automatically produce indicators for time-lapse to care instatement, of interest in the planning of
care in cancer. The next step will consist in evaluating this approach and extending it to more complex trajectories
(metastasis, relapse) and to other cancer localisations.
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Background
Care trajectories and guidelines
The care provided for patients with cancer requires a
multi-disciplinary approach. Throughout the course of
their illness, patients undergo a series of diagnostic in-
vestigations and surgical and medical treatments which
are all occasions for contact with the care system. They
follow care trajectories that vary according to geograph-
ical, temporal, institutional, medical, economic or social
factors. The trajectory can become more complex in
case of relapse or intercurrent illnesses, or it can be sim-
pler if the patient is cured or stabilises. In addition, an
optimal trajectory will depend on patient compliance,
avoidance of redundancy in investigations, prevention of
complications and delivery of appropriate therapies.
Clinical practice guidelines have been developed for this
purpose by groups of experts using updated information
from medical research along the lines of Evidence-Based
Medicine. The purpose of these guidelines is to reduce
variability in practices, control costs, and above all im-
prove the quality of care. Nevertheless, in actual oper-
ation, these recommendations are not always easy to
implement in settings where multidisciplinary care in-
volves several different professionals, or even several in-
stitutions. Indeed, the fact that recommendations exist
does not always mean that they are put into practice,
and there is the question of awareness of updates, and of
the need to comply with them [1].
Interest of modeling care trajectories
There is a need to describe, analyse and understand care
trajectories by modeling the itineraries followed by patients.
This process could also enable the evaluation of the appro-
priateness of care provision in relation to reference stan-
dards, and thus contribute to improving the organization of
healthcare and to determining strategic choices [2]. The
orientation of a patient through an optimized trajectory
does indeed depend on satisfactory coordination among
the different protagonists, and adequate planning of the
care itself. In France, cancer care is evolving towards the
formation of regional networks, so as to coordinate exper-
tise, services and resource allocation. The regional health
agencies (in France ARS –Agences Régionales de Santé) de-
fine and implement regional plans for hospital care aiming
to meet requirements of accessibility and quality. Time is
often a central element in care provision, which is why the
reduction of the time-lapse to instatement of care is a
major strategic orientation [3]. Modelling care trajectories
offers an explicit process-oriented view of healthcare and
will enable routine evaluation of the compliance of ob-
served care trajectories with those set out in guidelines.
The production of care trajectories and waiting-time indi-
cators at the regional population level should contribute to
improve care planning, ultimately ensuring that all patients
have access to the appropriate treatment within an appro-
priate time-lapse.
International context, computerization of medical data
and interoperability
The observation of the actual functioning of the care
system requires the existence of information systems
suited to following up patient care trajectories in a given
environment. Although numerous health information
systems have been set up in developed countries, they
were not specifically designed for this particular purpose.
Every year the care system generates enormous amounts
of data. The information required is fragmented and
spread across a number of sources. Yet there are few
tools able to mobilise and integrate this data for the pur-
pose of describing and modeling a set of care trajectories
that are characteristic of real-life patient trajectories.
The first work conducted in this area of health and on
the scale of a population was certainly that concerning
the classifications of patients, one of the first of which
was the DRG (Diagnosis Related Groups). These were
developed from the 1960s by Fetter [4], and the aim was
to define comparable care provision groups in which in-
dividuals were expected to use the same level of hospital
resources. These DRG led to numerous adaptations
across the world, for instance the PMSI in France
(Programme de Médicalisation des Systèmes d’Information),
and to a whole body of related research [5-7].
The representation of care trajectories using data min-
ing methods is a dynamic research area. These methods
are useful to seek sequential patterns corresponding to
the most frequent patient trajectories and to conduct
formal analysis of concepts enabling the description of
patient flows generating easily understandable graphical
representations [6-15]. While methods of data mining
aim to discover details in clinical trajectories or clinical
pathways, the number of patterns discovered need to be
restricted to the main stages defined by guidelines when
the objective is to provide routine evaluation indicators
of the compliance of observed care trajectories to guide-
lines. Clinical trajectories usually yield models restricted
to a single piece of hospital information system. To our
knowledge, there is no approach to date that has inte-
grated multiple-source data from all hospitals and health
structures involved in cancer care.
Cancer registry data
Internationally, cancer registries have achieved a high
degree of standardization of definitions, classification
systems, methods of analysis of data. This has been im-
portant in ensuring the comparability of incidence data
from cancer registries, and has enabled their increasing
use in epidemiological, clinical and health services man-
agement studies [16]. Most modern cancer registries use
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information sources on computer media at some point
in the data collection process. Work on the development
of a multi-source information system centred on the pa-
tient has been conducted to collect relevant information
for cancer case registration according to international
rules [17]. The General Cancer Registry of Poitou-
Charentes covers an administrative region of 1.8 million
people in south-western France. The increasing availabil-
ity of computerized information on cancer patients from
pathology databases, hospital administration systems
and other computerized data sources has led this regis-
try to extend its computer systems to exploit these new
opportunities.
Objectives
The main objective of this study was to develop a repre-
sentation of care trajectories over time for new cancer
patients, using the data from the Poitou-Charentes Re-
gional Cancer Registry information system, and to assess
the reliability and validity of this representation by con-
fronting trajectories derived from cancer registry data
used by the algorithm with observed care trajectories
documented from medical records. Since breast cancer
is the most frequent cancer in women in France [18]
and since it has been subject for many years to recom-
mendations based on updated survey data [19,20], we
chose to make a first illustration of an application of the
algorithm in the setting of non-metastatic breast cancer.
International registration rules
In compliance with national and international recom-
mendations [17], since January 1st 2008 the General
Cancer Registry of the Poitou-Charentes region (south-
western France) has included all the incident cases of
malignant tumour (haematological malignancies and
solid tumours not including baso-cellular skin carci-
nomas), involving subjects regularly residing in the
Poitou-Charentes region at the time of diagnosis.
Information system
The information system uses an Oracle 11 g database.
The data management procedures were developed in the
SAS environment (version 9.3).
The database of the cancer registry is a time-stamped
relational database storing medical data with the date of
occurrence of every event (such as date of admission,
date when a biopsy was performed). Temporal intervals
(such as the start, end and duration of a treatment)
are not directly available but can be computed from
the data.
The cancer registration database results from the investi-
gation of five types of electronic data sources in the Poitou-
Charentes area and in neighboring départements (Data
sources), where each data source comprises all facilities,
centers or establishments involved in cancer care to ensure
the completeness and the coverage of all areas of cancer
care for patients residing in Poitou-Charentes area.
A single program manages data capture in the system,
with distinction according to the formats of each source.
The integration process of data from different sources
for a given individual enables each source record to be
linked to the individual to which it belongs, performed
by an identity server (Computerised record linkage).
A single dataset has been created for the study of tem-
poral representation of care trajectories by extracting
from two of the five data sources (anatomical pathology
data and hospital discharge data), which concern 93 fa-
cilities or hospitals.
Data sources
The Registry has established collaboration with more
than 100 partners in the Region and in surrounding de-
partments. Five types of data sources, using various ter-
minologies to describe diagnosis, are routinely collected:
 Anatomical-pathology (AP) data (pathology data)
which includes free-text reports related to one or
several ADICAP diagnostic codes (Association pour
le Développement de l’Informatique en Cytologie et
en Anatomie Pathologique – the French classifica-
tion of lesions with topographical and histological
axis [21]) (n = 28 facilities).
 Hospital discharge (HD) data recorded in the
French medical information program (PMSI) [22]
which includes ICD-10 diagnostic codes and CCAM
medical procedure coded fields (Classification Com-
mune des Actes Médicaux – the health insurance
classification [23]) (n = 65 hospitals).
 Full reimbursement for cancer care granted by the
French healthcare insurance service (IS) which
includes ICD-10 diagnostic codes (n = 3 facilities).
 Data from cancer surveillance (CS) in cancer care
centres (“Centres de Lutte contre le Cancer”) which
includes ICD-O3 tumour codes. Cancer surveillance
is a system of data collection in oncology promoted
in France in 1975 by the National Federation of
Cancer Care Centers. It enables the identification of
topographic and histological diagnosis of tumours,
their initial extension, as well as therapeutic and out-
come data for all cases in a given cancer care center
(n = 3 centres).
 Data from Multidisciplinary Consulting Meetings
(MCM) which may or may not include ICD-10 diag-
nostic codes. Multidisciplinary Consulting Meetings
are held and serve for exchange among specialists
from different disciplines concerning the diagnostic
and therapeutic strategies to adopt for cancer pa-
tients. They are an essential part of the organisation
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of cancer care (n = 2 regional networks). These
meetings are known as Institutional Tumor Boards
in the United States.
Each of these bodies regularly transfers the informa-
tion required by the Registry in standardized structured
encrypted files. A single program manages data capture
in the system, distinguishing sources. The source data is
the most detailed level of information available in the
system.
Computerised record linkage
A primary function in the operation of a cancer registry
is to bring together information describing the same in-
dividual from a variety of data sources. Because multiple
notifications of the same tumour are expected if several
sources of information are used, effective procedures for
linking data on the same individual are very important,
minimizing duplicate registrations of the same tumour
and/or individual. So data extractions include patient
identity (name, surname, birthdate …). When loading
data in the registry information system, patient identities
are integrated into an identity server which by way of a
semi-automated process identifies data related to one
and the same patient. The patient identification process,
based on computerised record linkage [16], enables au-
tomated linkage (using deterministic rules), detection of
ambiguities, duplicate searches and manual patient
grouping or separation. This process enables all eligible
records from data sources integrated into the informa-
tion system to be related to single patients.
Cancer registration
A notification algorithm [24] determines, for each pa-
tient, the tumours that should be notified to cancer
registry staff according to registration rules for multiple
primary cancers [25] and already validated tumours.
Then each case is manually checked by registry staff by
visual inspection of information sources, assessing the
need to refer to a patient’s medical record to register the
tumour. Finally, all registered tumours contain relevant
information, including date of diagnosis, ICD-O3 topog-
raphy, ICD-O3 morphology and basis of diagnosis, and
they are systematically related to the data sources. Fol-
lowing this step, the source data related to non-
metastatic breast cancers can be selected on the basis of
this relationship to enable the representation of the care
trajectories.
Methods
Definitions
Care trajectory
The care trajectory is the term used to refer to the itinerary
of a patient through the healthcare system and among the
different actors over a continuous period from the onset of
the illness to its resolution [26]. In cancer care, the care tra-
jectory can comprise several successive episodes of care,
and this entails a distinction between the phases of diagno-
sis, treatment, consolidation, cure or local or distant
relapse.
Event and state
The representation algorithm developed is able to take ac-
count of each stage in the initial care provision for the
tumour. The method chosen consists in modelling the care
trajectory as an ordered succession of dated events aggre-
gated into states, the granularity of which is defined from
care provision guidelines.
An event is a phenomenon considered to be local and in-
stantaneous, occurring at a particular time-point. An event
is a time-stamped attribute (like a chemotherapy adminis-
tration, regardless of events occurring before of after).
When the event lasts over time, we refer to a state,
which is as a temporal interval with a start and an end.
A state corresponds to the aggregation of repeated oc-
currence of several events over time according to their
type and their chronology. A state corresponds to a
phase or a period in treatment, defined as a stage in the
initial care provision previously derived from guidelines.
For instance, the repeated occurrence of several events in
chemotherapy before surgery treatment is equivalent to the
definition of the state “neoadjuvant chemotherapy”.
Time scale
The time scale is determined by the information systems
searched, which here, as in most areas of health, date
the events occurring in the course of patient care ac-
cording to calendar days. Consequently, the smallest
measurable interval in the present study is the calendar
day, and a point event is represented as an interval of
one day.
Identification of standard sequences of initial care
provision for non-metastatic breast cancer
The main stages in the initial care provision for non-
metastatic breast cancer identified in the national guide-
lines [20] are listed below:
1. A diagnostic period involving pathology
investigations to confirm any suspected malignancy
following clinical and/or radiological examination.
2. A period of pre-surgery treatment for infiltrating,
voluminous and/or inflammatory cancers, indicated
to obtain initial reduction of tumour volume. It may
be envisaged for cancers that are non-operable at
the outset, or according to the size of the tumour,
so as to enable partial surgery . The reference treat-
ments are hormone therapy and chemotherapy.
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3. A surgery period, since as in the case of most
cancers the treatment of breast cancer is ideally
based on surgical removal of the tumour. This
removal should be accompanied by homolateral
axillary lymph node dissection. In case of an
infiltrating tumour of small size and in the absence
of palpable axillary adenopathy or suspect
ultrasound scan image, the sentinel lymph node
technique can be used. The surgical period also
involves pathology examination of the surgical piece,
conducted extemporaneously or following surgery,
and this enables confirmation of malignancy.
4. A post-surgery medical period covering different
therapies:
– Chemotherapy, mainly anthracyclines and taxanes,
is initiated 3 to 6 weeks after surgery, generally in 4
to 6 administrations 21 days apart, although patterns
can vary according to treatment protocols. Adjuvant
chemotherapy therefore lasts 9 to 15 weeks.
– HER2-targeted therapies, such as trastuzamab,
are indicated when there is significant HER2 over-
expression by the tumour. Depending on protocols,
the administration cycle can vary, and can be either
sequential, i.e. initiated after the chemotherapy, or
concomitant with the administration of taxanes.
The duration of administration is generally 1 year.
– Hormone therapy is only indicated in hormone-
sensitive tumours. The duration of treatment is
generally 5 years. Hormone therapy is initiated
after any chemotherapy and radiotherapy.
5. A radiotherapy period, involving irradiation of the
tumour site and of axillary lymph nodes for non-
metastatic breast cancer. The reference for all
volumes treated is 50 gy in 25 fractions over a period
of 33 days. The duration of radiotherapy can be in-
creased by one or two weeks in cases where the pa-
tient presents a risk of relapse. It is therefore
recommended that radiotherapy should be initiated
not more than 12 weeks after surgery if no chemo-
therapy is planned. If chemotherapy is indicated,
radiotherapy should be started not more than
5 weeks after the chemotherapy, and not more than
6 months after surgery. Neither immediate breast re-
construction nor prescription of targeted therapy
should alter these time lapses.
If these recommendations are synthesised, omitting
targeted therapies and hormone therapy which are ad-
ministered over long periods, it is possible to distinguish
three standard care sequences for non-metastatic breast
cancer, taking account of presence or absence of neo-
adjuvant or adjuvant medical treatment (Figure 1). These
standard sequences were constructed manually to define
the different states in non-metastatic breast cancer man-
agement that are expected to occur in cancer care trajec-
tories, and which are to be identified by the algorithm.
Representation of care trajectories
The procedures for the temporal representation of care
trajectories involve the following three stages:
1. Identification of tracer events in the care trajectory
for each individual within the source datasets.
2. Chronological aggregation of events into states
according to the level of granularity defined in
step 1.
3. Representation of care sequences in a simple form
(showing presence and order of states) and an
extended form (including the duration of states)
from which time lapses are calculated.
Identification of tracer events
Events in the course of chemotherapy or radiotherapy are
identified in HD data using ICD-10 diagnostic codes for
chemotherapy (Z511) and radiotherapy (Z510) linked to
the ICD-10 diagnostic code for breast cancer. For instance
(Z511-C509) in source data refers to a “chemotherapy”
event.
Surgical events – tumour removal, tumour and lymph
node removal, and lymph node removal alone are identified
in HD data from the 3rd alphanumerical character in
CCAM codes (defining the action performed) and linked to
ICD-10 code for breast cancer. For instance (C502-
QEFA001) in the source data refers to the event “tumour
and lymph node removal”.
Biopsy and surgery events are identified in AP data
from the first character in ADICAP codes (identifying
the sampling mode) for breast cancer. For example,
(ADICAP-OHGSA7B2) in the source data refers to the
event “surgery”.
In summary, HD data provide information on the na-
ture of the surgical act performed, and AP data enables
precise description of the act.
Chronological aggregation of events into states
So as to be able to model sequences and position them on
a temporal axis, we used a set of predefined relationships
according to a linear approach which includes the notion of
the time lapse [27,28]. The choice then was to retain only
one characterised event per point in time before aggregat-
ing, rather than generating more numerous different states.
This choice obeys the following hierarchy: tumour removal
and/or lymph node removal > chemotherapy and/or radio-
therapy > pathology sampling.
The aggregation takes account of the chronology of
events and complies with the following two rules:
Defossez et al. BMC Medical Informatics and Decision Making 2014, 14:24 Page 5 of 15
http://www.biomedcentral.com/1472-6947/14/24
– If an event occurs between two records that
would normally have been aggregated, the
aggregation is not performed. For instance, if the
patient undergoes surgery between two
chemotherapy sessions, the aggregation of these
two sessions into a “chemotherapy” state does
not occur.
– If the time-lapse between two events of the same
type is too long, the aggregation is not performed,
and this enables the differentiation of two distinct
care episodes (six months between two chemother-
apy administrations, one month between two radio-
therapy sessions, three months between two surgical
acts, three months between two pathology samples).
For instance if the patient has 3 months’ chemother-
apy following surgery, and then 1 year later another
3 months chemotherapy for a relapse, the algorithm
will differentiate the two successive chemotherapy
periods, and they will not be aggregated.
The rules for aggregating events into states are pre-
sented in Table 1. Because the main stages in the initial
care provision for the tumour are defined from care
provision guidelines, the relevance and completeness of
the states illustrated in Table 1 are ensured by expert
consensus.
It should be noted that a distinction is made for the
concomitant administration of radiotherapy and chemo-
therapy in one and the same report. This situation can
arise when HER2-targeted therapy is administered on
the occasion of a visit by the patient for radiotherapy.
The algorithm produces the specific state “chemotherapy-
radiotherapy” (CT-RT).
Representation of sequences
The sequences of states produced by the algorithm are
stored vertically in SPELL format [29], where a line rep-
resents a state and each state is characterised by a start
and an end. The data for each patient is then transposed
Figure 1 Standard care sequences for non-metastatic breast cancer. a: Care provision for non-metastatic breast cancer in case of good
prognosis (* excepting patients undergoing total mastectomy and with no relapse factors). b: Care provision for non-metastatic breast cancer in
case of presence of factors for poor prognosis. c: Care provision for non-metastatic breast cancer in case of voluminous, infiltrating and/or
inflammatory cancer.
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so as to present the whole sequence in the form of an
ordered chain of characters. An example of a representa-
tion of a care trajectory for a patient with infiltrating
ductal adenocarcinoma of the breast is shown in
Figure 2.
The sequences produced are available in two forms:
 A simple form in which the presence and order of
the states are shown.
 An extended form which integrates the duration of
states. This form includes periods without any event.
The chains of characters are extended by repeating
each character according to the duration of
the state.
The choice to represent care trajectories as chains of
characters where the length is directly proportional to
the duration of care provision enables simple calculation
of time-lapses via the use of PERL regular expressions
[30,31].
Evaluation of the representation of care trajectories
The quality of the representations of care trajectories
produced by the algorithm was assessed on a sample of
patients for whom the care trajectories were constructed
manually from data collected in the medical record (va-
lidation dataset). This dataset served as the reference
standard for the evaluation of the representation of care
trajectories. Each sequence was generated twice and in-
dependently from regional cancer registry data (auto-
matically as “algorithm sequences”) and from medical
record (manually as “observed sequences”). The per-
formance of the algorithm was assessed by confrontation
of the sequences generated by the algorithm with the
observed sequences for the patients (Figure 3).
Study population
The sample was formed by random selection stratified
on TNM extension stage at diagnosis. A minimum of 50
patients per stratum (TNM stages I, II and III) was re-
quested to conduct the evaluation of the algorithm in
order to cover a variety of care trajectories of patients
with breast cancer. The sample comprised 159 subjects
with unilateral non-metastatic breast cancer (TNM
stages I, II and III) diagnosed in 2008 among patients
residing in the Poitou-Charentes region at the time of
diagnosis, and who received all their care in three of
the five health territories in the region covered by the
Table 1 Main rules for aggregation of events into states
State code* State Type of event to aggregate
(time-lapse between two events for aggregation)
Dating
A AP ≥ 1 pathology investigations (less that 3 months apart)
Sampling Date
If several:
Start: date of first investigation
End: date of last investigation
C SURG ≥ 1 surgical acts (less than 3 months apart)
Date of the act
If several:
Start: date of first surgery
End: date of last surgery
D SURG_AP
≥ 1 surgical acts (less than 3 months) apart AND ≥ 1 pathology
investigations
Date of the act, or else date of the sample.
If several:
Start: date of first surgery
End: date of last surgery
N CT_NEO
≥ 1 administrations of chemotherapy occurring before the
first surgery
Start: date of the first administration
End: date of the last administration
K CT ≥ 1 administrations of chemotherapy (less than 6 months apart)
Start: date of the first administration
End: date of the last administration
R RT ≥ 1 radiotherapy sessions (less than 1 month apart)
Start: date of the first session
End: date of the last session
O CT_RT Period of concomitant radiotherapy and chemotherapy
Start: date of the first session of intercurrent RT
or CT
End: date of the last session of intercurrent RT
or CT
*Each state is recoded by a character so as to represent the overall sequence in the form of an ordered chain of characters.
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public radiotherapy unit (Vienne, Deux-Sèvres, Charente-
Maritime Sud).
Reconstruction of observed sequences
Whereas the algorithm-based sequences were produced
using solely the coded data from two electronic sources,
the 159 observed sequences were manually recon-
structed from the medical records, which collect all pa-
tient information produced and documented by staff
involved in patient care. For this work the cancer regis-
try staff systematically collected a copy of original path-
ology reports, surgery reports, hospitalisation reports or
other relevant reports needed for the documentation of
the main events in patient care trajectories. Each event
occurring between diagnosis and the end of initial care
provision for cancer was precisely documented (date and
result of pathological investigation, date and nature of
the surgical act, dates of start and end of chemotherapy,
radiotherapy, HER2-targeted therapy, hormone therapy,
number of sessions, alterations in treatment, occurrence
of complications). This documentation may be derived
from several different institutions depending on the
number of establishments frequented by the patient.
The states making up the sequence were then manu-
ally captured in a single data table using the same rules
implemented by the algorithm for the production of
Figure 2 Algorithm representing care trajectories. Figure 2 presents an illustration of the representation of the care trajectory for a patient
with infiltrating ductal adenocarcinoma of the breast. The diagnosis was established on examination of a biopsy by pathologists in a laboratory in
La Rochelle, Charente-Maritime (17CBLAR). Treatment was a sequence of neo-adjuvant chemotherapy (4 sessions) in Nantes cancer center, Loire
Atlantique (44CLRCC), followed by partial mastectomy and lymph node removal performed in Niort private hospital, Deux-Sèvres (79PCINK) and
then 30 sessions of irradiation in Niort general hospital, Deux Sèvres (79CHNIO). * LNR: Lymph Node Removal, (I) The extended form integrates
periods without any event noted I, where the start corresponds to the day following the previous state and the end to the day preceding the
following state.
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states. The observed trajectories were structured accord-
ing to the simple form and the extended form, to enable
confrontation with the trajectories produced by the
algorithm.
An endpoint for the end of treatment for each patient
was determined manually from the last state in the initial
care provision for the tumour. The endpoint of a trajectory
can correspond to the death of the patient if it occurs be-
fore the end of the initial course of treatment of the cancer.
Similarity measures
A similarity measure was performed on all pairs of tra-
jectories using the Levenshtein Edit Distance (LED) [32],
which enables comparison of chains of characters of dif-
ferent lengths using identical cost operations. The LED
is equal to the minimum number of characters that need
to be added, removed or replaced to switch from one
chain of characters to the other. Each of these elemen-
tary operations is associated with a cost equal to 1. The
LED function is available on SAS software using the
function COMPLEV.
Authorization and accreditation of the general cancer
registry of Poitou-Charentes
In conformity with French law, the collection and ana-
lysis of medical data by the General Cancer Registry of
Poitou-Charentes has received the approval of the
French regulatory authorities: the Comité Consultatif sur
le Traitement de l’Information en matière de Recherche
dans le Domaine de la Santé and the Commission Natio-
nale Informatique et Libertés (authorization number
907303).
In France, the Comité National des Registres (CNR)
evaluation grids to be applied for the accreditation of
registries include not only the methods used and the
quality of the records, but also the use made of the data,
and the interest and the originality of the research work
conducted [33]. The General Cancer Registry of Poitou-
Charentes has been approved by the French CNR since
January 2013 based on the 2008 and 2009 registered
data.
Results
Study population
The sample comprised 159 subjects with non-metastatic
breast cancer. The mean age at diagnosis was 64.0 ± 15.3
(range 30–94). Fifty-two per cent were between the ages of
50 and 75, corresponding to the age group eligible for
breast cancer screening from 2008. Fifty-five patients were
TNM stage I, 52 were TNM stage II and 52 were TNM
stage III.
Regional cancer registry data
(source datasets) Sample of 159 breast
Algorithm sequences
Simple form
Extended form
Representation of 
(chronological aggregation
according to the level
derived from clinical practice guidelines)
Algorithm
Evaluation by similarity
(Levenshtein Edit Distance)
Data collected from medical files
(medical reports)cancer patients
sequences
of events into states
of granularity
Observed sequences
Simple form
Extended form
Manually
measure
Figure 3 Strategy for evaluation of temporal representation of care trajectories. Target trajectories as observed sequences: trajectories
manually documented from medical files. Algorithm trajectories as algorithm sequences: trajectories automatically produced by the algorithm
from cancer registry source data.
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Description of the sequences observed in the sample
The sequences observed in the sample are shown in
Table 2. An individual care sequence belongs to one of
the three categories illustrated in Figure 1 when the
main tracer events are present in the same order as in
the standard care sequence. Variants can be expected ac-
cording to the presence or the absence of a pathology
investigation, such as biopsy (“A”) or a HER-targeted
therapy (“O”). Otherwise, sequences are classified as
non-standard sequences, and result in the particular
cases being described as the fourth category “Other
(non-standard sequences)”.
Ninety per cent of these sequences were identifiable in
the three standard sequences derived from recommen-
dations (Figure 1). All the sequences involving a period
of concomitant chemotherapy and radiotherapy (state
“CT-RT” coded O) correspond to patients treated with
HER2-targeted therapy.
More than half the observed (actual) sequences (51%
or 81 patients) corresponded to the standard “ADR” se-
quence which combines pathology examination for diag-
nostic purposes, a surgical act for removal of tumour
and/or lymph nodes, together with pathology examin-
ation of the surgical pieces, and radiotherapy treatment.
Among these 81 sequences, 21 patients had total mast-
ectomy, with biopsy (“AD”) or without (“D”), and no re-
lapse factor and hence absence of radiotherapy, while 13
patients had partial or total surgery on the basis of clin-
ical parameters, and relapse risk factors providing indi-
cation for radiotherapy (“DR”).
One third of the observed sequences (34% or 54 pa-
tients) corresponded to the standard “ADKR” sequence,
combining diagnostic pathology investigation, a surgical
act for removal of tumour and/or lymph nodes alongside
pathology examination of the surgical pieces, chemo-
therapy treatment and radiotherapy treatment. Two pa-
tients underwent surgery at the outset (“DKR”) and 10
were treated with HER2-targeted therapy, with biopsy
(“ADKOK”) or without (“DKOK”).
Eight patients followed the “ANDR” standard sequence
(5%) which associates diagnostic pathology examination,
neo-adjuvant chemotherapy, a surgical act for removal
of tumour and/or lymph nodes, with pathology investi-
gation of the surgical pieces, chemotherapy and then
Table 2 Description of observed (actual) sequences in the sample
Care sequences Numbers Percentage
Care provision for non-metastatic breast cancer in case of good prognosis (Figure 1a) 81 51%
ADR 47 30%
AD 16 10%
DR 13 8%
D 5 3%
Care provision for non-metastatic breast cancer in case of presence of factors for poor prognosis (Figure 1b) 54 34%
ADKR 42 26%
ADKOK 8 6%
DKR 2 1%
DKOK 2 1%
Care provision for non-metastatic breast cancer in case of voluminous, infiltrating and/or inflammatory cancer (Figure 1c) 8 5%
ANDR 8 5.0
Other (non standard sequences) 16 10%
A 6 5%
ADK 2 0-1%
AK 2 0-1%
AR 2 0-1%
ADKDR 1 0-1%
ANDRK 1 0-1%
DK 1 0-1%
DKDKOK 1 0-1%
A Pathology investigation.
D Surgery and pathology examination of the surgical pieces.
N Neo-adjuvant chemotherapy.
K Chemotherapy.
R Radiotherapy.
O Concomitant chemotherapy and radiotherapy.
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radiotherapy. Among these 8, 7 had a large and/or in-
flammatory carcinoma, and one patient expressed the
wish to preserve the breast.
Ten per cent of the remaining sequences (16 patients)
were particular cases:
– Ten patients who refused surgery, or whose
advanced age constituted a counter-indication for
surgery (“A”, “AK”, “AR”).
– For three patients, with and without secondary total
mastectomy (small breasts and areas surrounding
the exeresis not clear) the decision, justified in
MCM, was to administer chemotherapy but not
radiotherapy (“ADK”, “DK”).
– Two patients having undergone secondary surgery
at a late stage (“DKDKOK”, “ADKDR”).
– One patient who received HER2-targeted chemo-
therapy at a late stage “ANDRK”).
Performance of the algorithm
Pair similarity in simple sequences (simple form)
Ninety-eight per cent of the sequences generated by the
algorithm were similar to those observed when gener-
ated manually in terms of presence and ordering of
states, i.e. there were only three dissimilar sequences
among the 159 (LED = 1). These dissimilarities were re-
lated to absence of biopsy pathology report for one se-
quence (algorithm sequence “K” versus observed sequence
“AK”), and absence of pathology report for the surgical
pieces for two sequences (algorithm sequence “AC” versus
observed sequence “AD”).
Pair similarity in extended sequences (extended form)
Eighty-eight per cent of the identical sequences with re-
spect to presence and ordering of states were also simi-
lar to one day for the duration of the states, giving 18
dissimilar sequences out of 159 (LED median = 7.5,
range 1–51). The dissimilarities between sequences were
in 89% (16 of 18 patients) date errors, or absence of cod-
ing for chemotherapy sessions (LED 21–51) or radio-
therapy sessions (LED 1–3) at the start or the end of a
state. One patient had no HD data on the lymph node
removal she underwent secondarily (LED = 8). Finally,
one patient presented a date error of one day in the date
of surgery (LED = 1).
The percentage of match of pairs of extended se-
quences was 94% (10 dissimilar sequences out of 156) to
the nearest 3 days (LED = 3).
Discussion
This study presents a method for the temporal repre-
sentation of care trajectories for patients with non-
metastatic breast cancer using data from a regional
multi-source information system. The method proposed
enables identification of the main tracer events in a care
trajectory, and also integrates the duration of each event,
and the time-lapse between events making up the tra-
jectory. The results of the experiment show that the
algorithm is able to reconstruct the care trajectories
automatically from the registry data without implement-
ing a collection of relevant information in medical re-
cords, which would be very resource-consuming in this
setting.
Performance of the algorithm in the ordering of states
The ordering of treatment periods within the care se-
quences was correctly represented in 98% of cases. The
three discrepancies observed were linked to absence of
pathology evidence in the Registry data source, corre-
sponding to non-coded sampling procedures in the
pathology data (the practitioner did not code the
tumour), or to coding errors or inconsistencies. Two of
the dissimilar sequences nevertheless comprised all the
treatment periods, because the absence of a pathology
report on the surgical piece led to the creation of an
intermediate surgery state in the sequence (“C” - surgery
alone - rather than “D” - surgery and pathology evi-
dence). An earlier study [34] implemented a text cat-
egorisation method using a machine-learning technique
for the purpose of automatically categorising pathology
reports solely on their content, which has demonstrated
very good performances. It is therefore likely that the
performance of the algorithm could be improved further
by adding a supplementary check of the coding of
pathology reports.
Performance of the algorithm on the duration of states
The performance of the algorithm relating to the dur-
ation of states was 88% to the nearest day, and 94% to
three days, suggesting that the time-lapse indicators are
excellent for the main tracer events in a care trajectory.
The choice of representing care trajectories as chains of
characters where the length is directly proportional to
the duration of care provision makes it possible to ex-
tract and accurately calculate time-lapses in care trajec-
tories as required, on the basis of regular expressions.
Each regular expression needs to be drafted and adapted
to the type of time-lapse or treatment duration to be cal-
culated, thus enabling the main time-lapses to be pro-
duced for use in planning care in cancer units.
The dissimilarities between sequences were in 90% of
cases related to dating errors or absence of coding for
chemotherapy or radiotherapy sequences occurring at
the start or at the end of a state. The variability of the
dissimilarities observed was mechanically related to
treatment patterns. The dissimilarities ranged from 21 to
51 days according to the sequence when the coding er-
rors were linked to chemotherapy sessions, since the
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reference administration pattern is 9 to 15 weeks. Dis-
similarities were thus much smaller when the coding er-
rors concerned radiotherapy sessions (1 to 3 days
depending on sequences) since the reference pattern for
the volumes treated is 50 Gy in 25 fractions over 33 days.
Conversely, coding errors that persisted in the middle of
a state before aggregation had no impact on its duration.
Limitations
First, one limitation of this study is its restriction to only
three of the 5 health “territories” in the Poitou-Charentes
region, because of absence of data available relating to radi-
ology in private practice. Indeed, private radiology units bill
their activities on the basis of CCAM-coded acts per-
formed, and they are not covered by PMSI. The integration
of this activity into a database is essential because the share
of radiotherapy sessions performed on a profit-making basis
by private facilities was estimated to be 55% over the terri-
tory as a whole in 2002 [5]. There are no consequences on
the performances of the algorithm because the evaluation
was conducted on a sample of patients who received all
care in three of the five health territories in the region cov-
ered by the public radiotherapy unit. However, absence of
radiotherapy data from private establishments in the cancer
registry does not enable an evaluation of initial care trajec-
tories extended to all breast cancer patients living in
Poitou-Charentes area to be produced. We can however
hope that this data will be integrated into the Registry data-
base in the near future, since a reorganisation of the fund-
ing system for private-practice radiology is underway, and
the units that at present code their activities according to
CCAM will soon be required to produce standardised dis-
charge reports as under PMSI [35].
Second, representing care trajectories by way of a lin-
ear approach generates difficulties when therapies are
concomitant and when they are administered over long
periods. These problems can be managed by creating
composite states, with the risk of increasing the number
of different sequences. In the ICD-10 there is no distinc-
tion between classic chemotherapy and HER2-targeted
therapy, since both are coded Z511 for anti-tumour
chemotherapy. A supplementary state “CT-RT” was
therefore created to enable the representation, in this
particular instance, of a treatment period relating the
HER2-targeted therapy and concomitant radiology. This
choice proved to be opportune, since all the sequences
associating HER2-targeted therapy and radiotherapy
were correctly identified and restored by the algorithm.
Obviously, the creation of composite states will be dis-
cussed for each application of the algorithm to new
cancer localization.
Third, not all the relevant sources of cancer data were
included in modelling the trajectories. As can be seen
from the 10% non-identifiable sequences among standard
sequences from the different guidelines, the MCM are use-
ful for the identification of specific instances relating to
hospital care protocols, decisions linked to comorbidity, or
patient choices. The integration of the MCM into the rep-
resentation of sequences is also useful for the production of
time-lapses to post-surgery therapeutic proposals. This
source of data, although available at the time of study, was
not assessed for the exhaustiveness of its integration into
the Registry information system and therefore has not been
included in the analysis.
Fourth, today the Registry does not routinely collect data
relating to mammography, but it is working along these
lines with screening centres in the Poitou-Charentes region.
Bilateral mammography, the reference investigation in case
of clinical warning signs or in screening campaigns, would
be a very valuable element to include at the start of a trajec-
tory, so as to analyse the time-lapse to diagnosis (time be-
tween mammography and biopsy) or the time-lapses more
generally over the whole duration of care provision (for in-
stance the time-lapse between mammography and the end
of radiotherapy).
Comparison with the literature
Our modelling approach drew from work conducted in
the socio-economic sphere using sequence analysis
methods known as optimal matching, also known as se-
quence alignment, originally developed for rapid analysis
of proteins and DNA sequences [36]. The first optimal
matching algorithms appeared at the start of the 1970s,
and their first application in the social sciences dates
back to the article by Abbott and Forrest and their appli-
cation to historical data [37,38]. Many techniques and
tools, such as data mining, workflow mining or process
mining [6-15] give a conceptual framework for clinical
trajectory analysis. The aim of clinical trajectories is to
offer a flowchart format for the decisions to be made
and the care to be provided for a given patient or patient
group. All published methods sought to enumerate regu-
lar medical behaviors that are expected to occur in
patient-care trajectories from clinical workflow logs re-
corded by hospital information systems. But none to our
knowledge has performed an application on patient care
data in order to give an assessment of which regular
medical behaviors occur in patient-care trajectories in
real-life, rather than those expected. Moreover, they fre-
quently implement models that provide too much detail
to give a concise and comprehensive summary of the
trajectory and are usually restricted to a single hospital
information system. Our work focused on the represen-
tation of care trajectories through the main stages in the
initial care provision for non-metastatic breast cancer
identified in current updated guidelines, based on rele-
vant and accurate information from medical source re-
cords from all hospitals and health facilities involved in
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cancer care on a large geographical scale. To our know-
ledge this work is the first to assess the reliability and
the validity of an algorithm for the representation care
trajectories from cancer registry data. The method pro-
posed in this work responds to needs expressed by insti-
tutions and health professionals of routine indicators
aimed to improve the quality of patient care.
The structured organisation in the form of a relational
time-stamped database in the Poitou-Charentes cancer
Registry was well-suited to the application of these tech-
niques. The value of our study is that it models the care tra-
jectory from on-going routine collection of data for
exhaustive recording of incident cases of cancer. This ap-
proach is useful for routine manual registration of incident
tumours, because it makes relevant information available to
registry staff, information that is dated and presented in
chronological order, facilitating visual inspection of the case
and the identification of structures possessing complemen-
tary information, thus enabling cases to be recorded ac-
cording to international standards.
The routine production of care trajectories in cancer
and waiting-time indicators for the purpose of evalu-
ation, which are by-products of tumour notification to
the Registry, opens up new perspectives in terms of
cover, scope for comparison in time and space, and costs
of producing information. A recent French study pre-
sented an overview on regional level of time-lapses be-
tween the different acts and key steps in the trajectories
of patients with breast and lung cancer [39]. This study
underlined the time required to collect data, imposed by
the scatter of information for a given care trajectory, and
the difficulties linked to the heterogeneity of data collec-
tion methods and practices, so that routine short-term
follow-up of observed waiting times is not possible.
Similar approaches have been implemented in other
countries, for example in Ontario province, Canada, in
the UK, or in New Zealand [40-43]. These countries
have undertaken to study waiting times and estimate re-
ductions in time-lapses to treatment, which has become
one of the aims in their cancer Plans.
Certain specialised registries systematically record data
concerning the initial treatment. This is the case, for in-
stance, for breast cancer in the breast and gynaecological
cancer Registry of the Côte d’Or area in France. This
Registry used its database to supply information for a
study conducted within the Francim network of cancer
registries entitled “From diagnosis to first treatment:
time-lapse to instatement of care for cancers recorded
by the specialised registries in the Francim network
1999-2008”, recently published by Inca [44]. It showed
that there were variations in time-lapse to treatment
over this period.
However, the majority of the general registries do not
systematically collect information on care provision, and
do not therefore have any scope for generalising these
indicators unless a specific survey is conducted [45].
Perspectives
The routine production of these indicators will enable
regular assessment of the match between care provided
and official guidelines, the evaluation of time-lapse to
treatment, and comparison of results with those re-
ported in the international literature. This method can
be applied by other cancer registries, conditionally on
the availability of coded data sources using international
classification of disease (ICD-O-3, ICD-10).
The results presented in this study are in favour of a
continuation of this work on other cancer localizations.
Before implementing the algorithm on the population-
based cancer registry database for a new cancer loca-
lization, a further analysis of national guidelines and an
evaluation on a new sample of patients are required.
There are localisations where reducing time-lapse to
treatment instatement is a major strategic orientation,
and where providing care complying with guidelines re-
quires the histological type to be identified, as in lung
cancer. There are also rarer pathologies such as multiple
myeloma, where the application of the algorithm would
provide an overall picture of the organisation of the care
trajectory, the diversity of trajectories according to pa-
tient characteristics and the different players in the care
process. In our study the analysis was restricted to non-
metastatic breast cancer and to the initial care provision
for this cancer. Although rules were applied to avoid ag-
gregating two events of the same type belonging to two
different care episodes, the analysis needs to be extended
to care episodes following the initial care trajectory, such
as care relating to the occurrence of local or distant re-
lapse, thus approaching the notions of cure, relapse,
remission and consolidation.
Finally, one present limitation inherent in the repre-
sentation and analysis of care trajectories in cancer is
the absence of data on radiotherapy for private facilities,
and the absence of data on the administration of treat-
ment outside the hospital environment (oral chemother-
apy and other). Subsequent work should therefore study
the feasibility of obtaining and integrating SNIIR-AM
data (French national insurance information system) to
improve the representation of care trajectories among
cancer patients.
Conclusions
This study presents a temporal representation of care
trajectories in the form of a sequence of states ordered
in time. The system enables accurate, routine identifica-
tion of key dates and events in care trajectories, despite
the fact that the data is initially fragmented across nu-
merous sources in different territories. This information
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is collated in a single base from which it can be readily
extracted and exploited. The crossing of the trajectories
produced with certain clinical data will enable routine
evaluation of the compliance of observed care provision
trajectories with those set out in guidelines. The produc-
tion of indicators of this sort will contribute to sig-
nificantly improving care planning at regional level,
ultimately ensuring that all patients have access to the
appropriate treatment within an appropriate time-lapse.
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